Treating Acne: Advances in Retinoid Therapy

A supplement to Skin & Allergy News supported by an unrestricted educational grant from OrthoNeutrogena.
Highlights of presentations that took place at the 27th Annual Hawaii Dermatology Seminar.

•CME Recognition
•Contents
•Target Audience
•Educational Needs
•Learning Objectives

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 7.

CME Recognition

The Skin & Allergy News supplement “Treating Acne: Advances in Retinoid Therapy” is recognized by the American Academy of Dermatology for 1 hour of AAD Category 1 CME credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award. Term of approval: May 2003-April 2004.

This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines.
Contents

New Topical Acne Treatment
Judit Nyirady, MD
Clinical Director, Dermatology
Johnson & Johnson Consumer & Personal Products Worldwide
Skillman, NJ
Clinical Director, Dermatology: Johnson & Johnson Consumer and Personal Products Worldwide.

Topical Retinoids: Acne and Beyond
Hilary E. Baldwin, MD
Associate Professor of Clinical Dermatology
Department of Dermatology
State University of New York
Brooklyn, NY
Clinical Grant: OrthoNeutrogena. She discusses the investigational/off-label use of tretinoin microsphere gel and imiquimod.

Target Audience

This activity has been developed for dermatologists and other health care professionals involved in the treatment of acne vulgaris and other dermatological conditions.

Educational Needs

Retinoids have long been the mainstay of acne therapy. A wide variety of topical formulations is available, each providing a different therapeutic index but generally aiming to maximize efficacy while minimizing cutaneous irritation. A new low-does (0.04%) tretinoin microsphere gel has been introduced that offers significant anti-acne efficacy without substantial skin irritation. To optimize patient treatment plans, dermatologists must appreciate the range of available treatment options as well as the substantial therapeutic benefit of a nonirritating retinoid in a variety of dermatological conditions.

Learning Objectives

By reading and studying this supplement, participants should be able to:

• Discuss clinical studies involving low-dose tretinoin gel in patients with acne vulgaris.

• Distinguish risk (irritation potential)-benefit (anti-acne efficacy) relationships among commercially available topical retinoid formulations.

• Describe the therapeutic advantages of nonirritating topical retinoids in a variety of clinical conditions.

Copyright © 2003 by International Medical News Group

---